139 related articles for article (PubMed ID: 8342580)
1. Mineralocorticoid therapy lowers serum potassium in patients with end-stage renal disease.
Singhal PC; Desroches L; Mattana J; Abramovici M; Wagner JD; Maesaka JK
Am J Nephrol; 1993; 13(2):138-41. PubMed ID: 8342580
[TBL] [Abstract][Full Text] [Related]
2. Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis.
Kim DM; Chung JH; Yoon SH; Kim HL
Nephrol Dial Transplant; 2007 Nov; 22(11):3273-6. PubMed ID: 17616536
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
Kaisar MO; Wiggins KJ; Sturtevant JM; Hawley CM; Campbell SB; Isbel NM; Mudge DW; Bofinger A; Petrie JJ; Johnson DW
Am J Kidney Dis; 2006 May; 47(5):809-14. PubMed ID: 16632019
[TBL] [Abstract][Full Text] [Related]
4. Treating interdialytic hyperkalemia with fludrocortisone.
Imbriano LJ; Durham JH; Maesaka JK
Semin Dial; 2003; 16(1):5-7. PubMed ID: 12535291
[TBL] [Abstract][Full Text] [Related]
5. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis.
Furuya R; Kumagai H; Sakao T; Maruyama Y; Hishida A
Nephron; 2002; 92(3):576-81. PubMed ID: 12372940
[TBL] [Abstract][Full Text] [Related]
6. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients.
Kim HJ
Nephron; 1996; 72(3):476-82. PubMed ID: 8852501
[TBL] [Abstract][Full Text] [Related]
7. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
[TBL] [Abstract][Full Text] [Related]
8. Potassium-lowering effect of albuterol for hyperkalemia in renal failure.
Montoliu J; Lens XM; Revert L
Arch Intern Med; 1987 Apr; 147(4):713-7. PubMed ID: 3827459
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hyperkalemic RTA in pediatric post-renal transplant patients and the role of fludrocortisone.
Alabdulqader MA; Azzam A; Alshami AA
Pediatr Transplant; 2021 Sep; 25(6):e14029. PubMed ID: 34021680
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hyperkalemia among hemodialysis patients in Egypt.
Khedr E; Abdelwhab S; El-Sharkawy M; Ali M; El Said K
Ren Fail; 2009; 31(10):891-8. PubMed ID: 20030523
[TBL] [Abstract][Full Text] [Related]
11. Comparison of aminophylline and insulin-dextrose infusions in acute therapy of hyperkalemia in end-stage renal disease patients.
Mahajan SK; Mangla M; Kishore K
J Assoc Physicians India; 2001 Nov; 49():1082-5. PubMed ID: 11868861
[TBL] [Abstract][Full Text] [Related]
12. Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients.
Vlassopoulos D; Sonikian M; Dardioti V; Pani I; Hadjilouka-Mantaka A; Hadjiconstantinou V
Ren Fail; 2001 Nov; 23(6):833-42. PubMed ID: 11777323
[TBL] [Abstract][Full Text] [Related]
13. Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients.
Dick TB; Raines AA; Stinson JB; Collingridge DS; Harmston GE
Transplant Proc; 2011 Sep; 43(7):2664-8. PubMed ID: 21911143
[TBL] [Abstract][Full Text] [Related]
14. Hyperkalemia in chronic peritoneal dialysis patients.
Elliott AB; Soliman KMM; Ullian ME
Ren Fail; 2022 Dec; 44(1):217-223. PubMed ID: 35166182
[No Abstract] [Full Text] [Related]
15. Nonselective Beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients.
Nowicki M; Miszczak-Kuban J
Nephron; 2002 Jun; 91(2):222-7. PubMed ID: 12053057
[TBL] [Abstract][Full Text] [Related]
16. Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study.
Yusuf AA; Hu Y; Singh B; Menoyo JA; Wetmore JB
Am J Nephrol; 2016; 44(3):179-86. PubMed ID: 27592170
[TBL] [Abstract][Full Text] [Related]
17. Severe hyperkalemia following adrenalectomy for aldosteronoma: prediction, pathogenesis and approach to clinical management- a case series.
Tahir A; McLaughlin K; Kline G
BMC Endocr Disord; 2016 Jul; 16(1):43. PubMed ID: 27460219
[TBL] [Abstract][Full Text] [Related]
18. Intravenous infusion or nebulization of salbutamol for treatment of hyperkalemia in patients with chronic renal failure.
Liou HH; Chiang SS; Wu SC; Yang WC; Huang TP
Zhonghua Yi Xue Za Zhi (Taipei); 1994 May; 53(5):276-81. PubMed ID: 8039040
[TBL] [Abstract][Full Text] [Related]
19. Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients.
Farese S; Kruse A; Pasch A; Dick B; Frey BM; Uehlinger DE; Frey FJ
Kidney Int; 2009 Oct; 76(8):877-84. PubMed ID: 19641483
[TBL] [Abstract][Full Text] [Related]
20. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
